Over the last two decades, the frontline therapy for mantle cell lymphoma (MCL) has evolved. However, the impact of subsequent lines of therapy on survival outcomes has not been well characterized. In this study, we investigated the treatment patterns and survival outcomes in patients with relapsed/refractory (R/R) MCL treated with second-line (2 L) therapy. Adult patients with newly diagnosed MCL from 2002 to 2015 were enrolled in a prospective cohort study. Clinical characteristics, 2 L treatment details, and outcomes were compared between patients who received 2 L treatment between 2003–2009 (Era 1), 2010–2014 (Era 2), and 2015–2021 (Era 3). 2 L treatment was heterogenous in all eras, and there was a substantial shift in the pattern of 2 L therapy over time. The estimated 2-year EFS rate was 21% (95% CI, 13–35), 40% (95% CI, 30–53), and 51% (95% CI, 37–68) in Era 1–3 respectively, and the 5-year OS rate was 31% (95% CI, 21–45), 37% (95% CI, 27–50), and 67% (95% CI, 54–83) in Era 1–3, respectively. These results provide real-world evidence on evolving treatment patterns of 2 L therapy based on the era of relapse. The changes in 2 L treatment correlated with improved EFS and OS, suggesting that treatment advances are associated with improved outcomes in patients with R/R MCL.
在过去的二十年中，套细胞淋巴瘤（MCL）的一线治疗方案不断发展。然而，后续治疗对患者生存结局的影响尚未得到充分描述。本研究探讨了接受二线（2L）治疗的复发/难治性（R/R）MCL患者的治疗模式与生存结局。本研究纳入2002年至2015年新确诊的成年MCL患者，开展了一项前瞻性队列研究。比较了在2003–2009年（时期1）、2010–2014年（时期2）和2015–2021年（时期3）接受2L治疗患者的临床特征、2L治疗细节及结局。所有时期的2L治疗方案均呈现异质性，且其模式随时间发生显著变化。时期1至时期3的估计2年无事件生存（EFS）率分别为21%（95% CI，13–35）、40%（95% CI，30–53）和51%（95% CI，37–68），5年总生存（OS）率分别为31%（95% CI，21–45）、37%（95% CI，27–50）和67%（95% CI，54–83）。这些结果为基于复发时期的2L治疗模式演变提供了真实世界证据。2L治疗的变化与EFS和OS的改善相关，表明治疗进展与R/R MCL患者结局的改善存在关联。
肿瘤(癌症)患者之家